38.Boos CJ, Carlsson J, More RS. Rate or rhythm control in persistent atrial fibrillation? QJM 2003;96:881-92.
39.Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J 2002;144:597-607.
40.Levine TB, Bernink PJ, Caspi A, et al. Effect of mibefradil, a Ttype calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study:Mortality Assessment in Congestive Heart Failure Trial. Circulation 2000;101:758-64.
41.Masoudi FA, Havranek EP, Smith G, et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003;41:217-23.
42.Clinical Quality Improvement Network Investigators. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure: the relative importance of age, sex, and medical therapy. Arch Intern Med 1996;156:1669-73.
43.Herholz H, Goff DC, Ramsey DJ, et al. Women and Mexican Americans receive fewer cardiovascular drugs following myocardial infarction than men and non-Hispanic whites: the Corpus Christi Heart Project, 1988-1990. J Clin Epidemiol 1996;49:279-87.
44.Witzig R. The medicalization of race: scientific legitimization of a flawed social construct. Ann Intern Med 1996;125:675-9.
45.Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE,Domanski MJ. Racial differences in the outcome of left ventricular dysfunction [published erratum appears in N Engl J Med 1999;341:298]. N Engl J Med 1999;340:609-16.
46.Alexander M, Grumbach K, Remy L, Rowell R, Massie BM.Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. Am Heart J1999;137:919-27.
47.Insuficiencia Cardiaca., Diagnóstico y tratamiento.Editorial Ciencias Médicas.2007 ecimed@infomed.sld.cu
48.Hipertensión arterial.Guía para la prevención, diagnóstico y tratamiento..Comisión Nacional Técnica Asesora del programa de Hipertensión arterial..La Habana : Editorial Ciencias Médicas, 2008.ecimed@infomed.sld.cu
49.Teerlink JR, Massie BM. Late breaking heart failure trials from the 2003 ACC meeting: EPHESUS and COMPANION. J Card Fail 2003;9:158-63.
50.Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49.
51.Unverferth DV, Magorien RD, Moeschberger ML, Baker PB,Fetters JK, Leier CV. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol 1984;54:147-52.
52.Nelson GS, Berger RD, Fetics BJ, et al. Left ventricular or biventricularpacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundlebranchblock. Circulation 2000;102:3053-9.
53.Vitarelli A, Tiukinhoy S, Di LS, Zampino M, Gheorghiade M.The role of echocardiography in the diagnosis and management of heart failure. Heart Fail Rev 2003;8:181-9.
54.Ritchie JL, Bateman TM, Bonow RO, et al. Guidelines for clinical use of cardiac radionuclide imaging: report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol 1995;25:521-47.
55.Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366-74.
56.Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002;40:1531-40.
57.Butler J, Khadim G, Paul KM, et al. Selection of patients for heart transplantation in the current era of heart failure therapy. J Am Coll Cardiol 2004;43:787-93.
58.The Criteria Committee of the New York Heart Association.Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis. 6th ed. Boston, Mass: Little Brown; 1964.
59.Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002;360:1037-43.
60.Massie BM, Armstrong PW, Cleland JG, et al. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial: the Assessment of Treatment with Lisinopril and Survival. Arch Intern Med 2001;161:165-71.